Hyperammonemia Management
Introduction
- Hyperammonemia is a life-threatening condition that requires prompt diagnosis and treatment, with the goal of reducing blood ammonia levels and preventing neurological damage, as recommended by the European Society of Intensive Care Medicine 1
Dialysis Methods
- High-dose CVVHD (continuous venovenous hemodialysis) is recommended as first-line treatment for hyperammonemic patients, providing more stable clearance with less rebound hyperammonemia compared to HD, according to the Nature Reviews Nephrology 1
- Continuous Kidney Replacement Therapy (CKRT) is effective in rapidly reducing blood ammonia levels in hyperammonemic patients, and is associated with less rebound compared to HD due to its continuous nature 1
- Peritoneal Dialysis (PD) is less effective than HD or CKRT but can still reduce ammonia levels, and may be used when vascular access is difficult 1
- Hemodialysis can decrease blood ammonia by 75% within 3-4 hours, and is indicated for rapidly deteriorating neurological status, coma or cerebral edema, ammonia levels >1,000 μmol/L, and failure to respond to pharmacological therapy 1
Dialysis Prescription and Timing
- For levels >400 μmol/L refractory to medical management, initiate CKRT, and switch from HD to CKRT once ammonia levels are <200 μmol/L on two consecutive hourly measurements 1
- CKRT should be used with high-dose CVVHD with blood flow (Qb) 30-50 ml/min and dialysate flow/blood flow ratio (Qd/Qb) >1.5 1
- Early initiation of dialysis is crucial, as the duration of hyperammonemic coma is a key prognostic factor 1
The following conditions require initiation of CKRT:
| Condition | Blood Ammonia Level | Treatment | | --- | --- | --- | | Rapidly deteriorating neurological status | >150 μmol/L | Initiate CKRT | | Coma or cerebral edema | >150 μmol/L | Initiate CKRT | | Moderate or severe encephalopathy | >400 μmol/L | Initiate CKRT | | Rapid rise in blood ammonia levels | >300 μmol/L | Initiate CKRT | | Rebound hyperammonemia | - | Continue nitrogen-scavenging agents during dialysis | 1
Patient Considerations
- Vascular access is required for CKRT, which may be challenging in neonates 1
- CKRT provides better hemodynamic stability than HD, especially important in critically ill patients 1
- Warming the dialysate helps maintain hemodynamic stability, particularly in neonates 1
- Malnutrition is common and associated with poor prognosis in alcoholic hepatitis, and patients should receive adequate calories (35-40 kcal/kg of body weight daily) 2
- Consider tube feeding if oral intake is inadequate in patients with liver disease 2
Medications and Supplements
- Rifaximin may be added to lactulose for treatment of hepatic encephalopathy in patients with liver disease 2
- Sodium benzoate dosage is based on body weight, with 250 mg/kg for body weight <20 kg and 5.5 g/m² for body weight >20 kg, given over 90 min as bolus then as maintenance over 24 hours, with a maximum dose of 12 g daily, as recommended by the American Association for the Study of Liver Diseases 1
- Sodium phenylacetate dosage is also based on body weight, with 250 mg/kg for body weight <20 kg and 5.5 g/m² for body weight >20 kg, given over 90 min as bolus then as maintenance over 24 hours, as recommended by the American Association for the Study of Liver Diseases 1
- L-arginine hydrochloride is used for urea cycle disorders, with specific dosages based on the type of deficiency and patient weight, as recommended by the American College of Physicians 1
- Alcohol abstinence is the cornerstone of therapy for patients with alcoholic hepatitis, and supplementing with B-complex vitamins can prevent Wernicke's encephalopathy 2
- Avoid nephrotoxic drugs and diuretics to prevent acute kidney injury in patients with liver disease, and avoid beta-blockers in patients with severe alcoholic hepatitis as they may increase the risk of acute kidney injury 2
Monitoring and Prognosis
- Measure ammonia levels and assess neurological status using the Glasgow Coma Scale in patients with suspected hyperammonemia, as recommended by the European Society of Intensive Care Medicine 1
- Check ammonia levels at 24 hours and 5-7 days, and monitor neurological status, as recommended by the American Association for the Study of Liver Diseases 1
- The duration of hyperammonemic coma and plasma ammonia levels are key prognostic factors, with adverse prognostic factors including hyperammonemic coma lasting >3 days, increased intracranial pressure, and plasma ammonia level >1,000 μmol/L, as recommended by the European Society of Intensive Care Medicine 1
The following clinical scenarios require recommended actions:
| Clinical Scenario | Ammonia Level | Recommended Action | |-------------------|---------------|-------------------| | Rapidly deteriorating neurological status | >150 μmol/L | Initiate CKRT | | Moderate/severe encephalopathy | Any level | Consider treatment | | Persistently high levels | >400 μmol/L | Initiate CKRT if refractory to medical management | | Rapid rise in levels | >300 μmol/L | Initiate CKRT if uncontrolled by medical therapy | 3
Supportive Care
- Ensure adequate volume replacement and maintain mean arterial pressure, as suggested by a medical guideline society, and use vasopressors (dopamine, epinephrine, norepinephrine) as needed, correcting electrolyte abnormalities, particularly glucose, potassium, magnesium, and phosphate, as recommended by a medical society 4, 5
- Treat acid-base disturbances, and consider high-dose vitamin D3 supplementation in critically ill patients with measured low levels, as suggested by a medical guideline society, and administer vitamin K (at least one dose) in coagulopathic patients, performing surveillance for infections (common trigger for encephalopathy) 6, 4
- Administer appropriate antibiotics promptly when infection is identified, and consider antibiotic prophylaxis in high-risk patients, as suggested by a medical guideline society 7, 4